← Leaderboards
Smriti Mehra
Texas Biomedical Research Institute
$10,904,439
Attributed
$13,371,062
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,371,062 · 9
By mechanism
R01$12,012,077 · 3
R21$852,445 · 3
P20$414,115 · 1
U42$92,425 · 2
Top collaborators
- William Ramses Bishai5 shared
Most similar at Texas Biomedical Research Institute
Same institution · by research overlap
- Dhiraj Kumar Singh$3,900,756
- John Charles Bernal$0
- Shelley A Cole$12,006,201
- Riti Sharan$2,085,261
- Larry S. Schlesinger$102,133,846
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingMycobacterium TuberculosisResponseTuberculosis VaccinesImmunityTuberculosisMacrophageImmunePreventAdultInfectionImmune ResponseTuberculosis GranulomaPulmonary TuberculosisMacacaInflammatoryAnimalsRouteNonhuman PrimateAcquired Immunodeficiency SyndromeMyeloid CellsPathologyProgramsCessation Of Life
Grant awards (22)
Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection$905,874
R01 · FY2025 · AI · contact PI
Viral Testing Core$30,808
U42 · FY2025 · OD · contact PI
A STINGing vaccine for TB$1,068,965
R01 · FY2024 · AI
Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection$914,927
R01 · FY2024 · AI · contact PI
Viral Testing Core$30,808
U42 · FY2024 · OD · contact PI
A STINGing vaccine for TB$1,161,477
R01 · FY2023 · AI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$1,130,921
R01 · FY2023 · AI · contact PI
Viral Testing Core$30,809
U42 · FY2023 · OD · contact PI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$1,260,778
R01 · FY2022 · AI · contact PI
A STINGing vaccine for TB$1,051,436
R01 · FY2022 · AI
A STINGing vaccine for TB$808,927
R01 · FY2021 · AI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$1,077,090
R01 · FY2020 · AI · contact PI
A STINGing vaccine for TB$842,441
R01 · FY2020 · AI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$916,047
R01 · FY2019 · AI · contact PI
Indoleamine dioxygenase suppresses pulmonary T-cell immunity to Mycobacterium tuberculosis$414,115
P20 · FY2019 · GM · contact PI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$866,688
R01 · FY2018 · AI · contact PI
Role of IDO in tryptophan pathway during Mycobacterial Tuberculosis infection$240,435
R21 · FY2018 · AI · contact PI
Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma$6,506
R01 · FY2018 · AI · contact PI
"Role of IDO in tryptophan pathway during Mycobacterial tuberculosis infectionâ$5,692
R21 · FY2018 · AI · contact PI
"Role of IDO in tryptophan pathway during Mycobacterial tuberculosis infectionâ$202,566
R21 · FY2017 · AI · contact PI
Correlates of protection from TB and TB/AIDS comorbidity$237,215
R21 · FY2016 · AI · contact PI
Characterization of Protective Immunity to MTB in a Setting of HIV Coinfection$166,537
R21 · FY2016 · AI · contact PI